PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide that works as a melanocortin receptor agonist. The FDA-approved product is Vyleesi, which treats hypoactive sexual desire disorder (HSDD) in premenopausal women. It is grouped under the following drug class(es): Compounded peptides and Peptides. Its therapeutic use is listed as compounding pharmacy peptides and sexual dysfunction agents. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Vyleesi, PT141 acetate and PT-141. Its PubChem CID is 91971505.
Bremelanotide acetate (PT-141)
| CAS No | 1607799-13-2 |
|---|---|
| Molecular Formula | C52H72N14O12 |
| Molecular Weight | 1085.2 g/mol |
| Synonyms | (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid;acetic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide that works as a melanocortin receptor agonist. The FDA-approved product is Vyleesi, which treats hypoactive sexual desire disorder (HSDD) in premenopausal women.
The listed CAS number is 1607799-13-2.
The listed molecular formula is C52H72N14O12.
The listed molecular weight is 1085.2 g/mol.
(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid;acetic acid.
The source lists Vyleesi, PT141 acetate and PT-141.